Similarly, updated findings from the KEYNOTE - 811 trial reported at ASCO 2024 confirmed that pembrolizumab combined with trastuzumab and chemotherapy significantly improved objective response rate (ORR) and progression-free survival (PFS) in HER2-positive gastric cancer. This evidence concerns the gene ERBB2 and gastric cancer.